Inhibikase Therapeutics (IKT) Interest & Investment Income (2022)

Inhibikase Therapeutics (IKT) reported Interest & Investment Income of $18536.0 for Q3 2022.

Inhibikase Therapeutics (IKT) Interest & Investment Income (2022) Analysis & Trends

Inhibikase Therapeutics (IKT) has 1 years of Interest & Investment Income data on file, last reported at $18536.0 in Q3 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int & Inv Inc (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - 597,319.59
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 40.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - 305,000.00
7 Psyence Biomedical 227.32 Bn 227.31 Bn - 103,341.00
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn 114.80 Mn
9 Abivax 91.71 Bn 91.71 Bn - -14.79 Mn
10 Inhibikase Therapeutics 285.17 Mn 114.80 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2022 18,536.00